Fallopian Tube News and Research

RSS

BC gynecologists initiate campaign to reduce ovarian cancer mortality

Gynecologic oncologists with the Ovarian Cancer Research Program at Vancouver General Hospital (VGH) and the BC Cancer Agency have begun an important campaign that will reduce deaths from ovarian cancer.

9 Sep 2010

Preventive surgery protects against breast, ovarian cancer in women carrying BRCA1, BRCA2 gene mutations

Women who have gene mutations that put them at high risk of ovarian and breast cancer can significantly reduce the risk of developing or dying from these cancers by having their healthy ovaries or breasts removed, according to a new study reported in the Sept. 1 issue of the Journal of the American Medical Association.

3 Sep 2010

GOG to conduct Phase II trial on primary peritoneal cancer

Oncolytics Biotech Inc. announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H).

3 Sep 2010

Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that a second large, Phase III, international study showed that the combination of Avastin® (bevacizumab) and chemotherapy, followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening (progression-free survival or PFS, the primary endpoint), compared to chemotherapy alone.

2 Jul 2010

Combination of reovirus and carboplatin/paclitaxel shows promising anticancer activity in SCCHN

Oncolytics Biotech Inc. announced today that abstracts covering clinical research with reovirus (REOLYSIN(R)) are available on the American Society of Clinical Oncology website at www.asco.org, and on the Oncolytics website at www.oncolyticsbiotech.com.

21 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

FDA approves Conceptus' ESS305 Essure procedure for increased bilateral placement rate of 96.9%

Conceptus Inc., developer of the Essure(R) procedure, the first and proven non-surgical permanent birth control method, announced today that the third generation (ESS305) of the Essure procedure has received FDA-approval for an improved bilateral placement rate of 96.9%. Improvement in the hysteroscopic time of 9 minutes is an additional benefit.

19 May 2010

NCCN Guidelines: Chemosensitivity/resistance assays to be part of Principles of Chemotherapy section

Precision Therapeutics announced today that The National Comprehensive Cancer Network® recently updated the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer to include the use of chemosensitivity/resistance assays as part of the Principles of Chemotherapy section.

26 Feb 2010

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin.

25 Feb 2010

NCCN updates the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer

The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology™ for Ovarian Cancer to reflect the addition of two preferred combination regimens for a specific cohort of patients based on data from recent clinical research studies.

27 Jan 2010

Gently rocking embryos during IVF may improve success rates

Gently rocking embryos while they grow during in vitro fertilization (IVF) improves pregnancy rates in mice by 22 percent, new University of Michigan research shows. The procedure could one day lead to significantly higher IVF success rates in humans.

20 Jan 2010

New procedure could lead to higher IVF success rates in humans

19 Jan 2010

IntegraMed America plans to open new vein clinic in Columbia, Maryland

IntegraMed America, Inc., the nation’s leading manager of specialty outpatient healthcare facilities in the emerging, technology-focused medical niches of fertility and vein care, today announced plans to open a new vein clinic in Columbia, Maryland in mid 2010.

9 Jan 2010

Cook Medical launches FluoroSet for accurate fluoroscopic evaluation results

Approximately one million women in the United States are rendered infertile by disease in the fallopian tubes, the most common being tubal occlusion or blockage. This condition is commonly diagnosed using a complicated, invasive fluoroscopic evaluation, consisting of real-time, action images of the fallopian tubes to identify possible occlusions. In an effort to simplify this procedure and ease patient discomfort, Cook Medical today announced the availability of the FluoroSet, a comprehensive, three-product radiographic tubal assessment set designed to deliver fast, easy, accurate fluoroscopic evaluation results.

26 Oct 2009

FDA approves Hologic's permanent contraception system

Hologic, Inc.today announced the U.S. Food and Drug Administration (FDA) has approved the Company's premarket approval (PMA) application for the Adiana permanent contraception system.

From Hologic, Inc. 7 Jul 2009

First baby born after new ovarian transplant technique

A new technique for transplanting the ovaries of women who have lost their fertility as a result of cancer treatment was outlined to the 25th annual conference of the European Society of Human Reproduction and Embryology today (Monday 29 June).

29 Jun 2009

Fallopian tubes: a new source of multipotent adult mesenchymal stem cells

Human tissues normally discarded after surgical procedures could be a rich additional source of stem cells for regenerative medicine. New research from BioMed Central's open access Journal of Translational Medicine shows for the first time that human fallopian tubes are abundant in mesenchymal stem cells which have the potential of becoming a variety of cell types.

17 Jun 2009

Image-guided treatment helping women with tubo-ovarian abscesses avoid unnecessary surgery

Image guided drainage of tubo ovarian abscesses help women avoid surgery, according to a study performed at Massachusetts General Hospital in Boston, MA.

23 Apr 2009

Possible new methods to enhance the success rate of fertility treatments

As hopeful moms-to-be learn, there are important considerations to the successful implantation of a fertilized human egg.

2 Mar 2009

Research confirms value of risk-reducing salpingo-oophorectomy for women with BRCA mutations

Prophylactic salpingo-oophorectomy-removal of the ovaries and fallopian tubes--reduces the relative risk of breast cancer by approximately 50 percent and the risk of ovarian and fallopian tube cancer by approximately 80 percent in women who carry a mutation in the BRCA1 or BRCA2 gene, researchers report in the January 13 online issue of the Journal of the National Cancer Institute.

13 Jan 2009